Answers are grounded in this paper and cite their sources.
Simultaneously determined total serum prostatic acid phosphatase (TSPAP) and tartrate-labile prostatic phosphatase (PAP) values were determined in 326 randomly selected patients, with histologically verified BPH (141 cases) or carcinoma of the prostate (185 cases). Unexplained elevations in TSPAP were noted in 7% of BPH cases. A 2.7% incidence of similar unexplained elevated PAP values was observed. However, in prostatic carcinoma cases, TSPAP was increased above normal range in 63.8% while PAP values were elevated in only 41.1%. When prostatic carcinoma cases are subdivided according to the clinical stage of the disease, TSPAP values are still consistently elevated to a greater degree than PAP at all clinical stages, with and without metastases. Regardless of the differentiation of the prostatic tumor, TSPAP levels were always more frequently elevated than PAP values. Tartrate-labile prostatic acid phosphatase (PAP) determinations are thus of no greater value in the diagnosis of prostatic carcinoma. In fact, total serum prostatic acid phosphatase is more sensitive and correlates better to the clinical stage of the disease and degree of differentiation of the primary tumor.
No takes yet. Share an insight, caveat, or question.
Murphy et al. (1969) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: